ACRV — Acrivon Therapeutics Balance Sheet
0.000.00%
- $51.42m
- -$128.06m
- 29
- 53
- 22
- 26
Annual balance sheet for Acrivon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1.58 | 99.6 | 128 | 127 | 179 |
Prepaid Expenses | |||||
Total Current Assets | 1.72 | 100 | 132 | 130 | 182 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.059 | 5.79 | 6.86 | 7.91 | 8.03 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 2.19 | 107 | 181 | 138 | 197 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.613 | 2.91 | 6.52 | 13.3 | 17.2 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.931 | 7.88 | 10.8 | 17.1 | 19.8 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1.25 | 98.7 | 170 | 121 | 177 |
Total Liabilities & Shareholders' Equity | 2.19 | 107 | 181 | 138 | 197 |
Total Common Shares Outstanding |